A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer

by | Nov 4, 2026 | Clinical Trials | 0 comments

​ Conditions: CRC

Interventions: Drug; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276

Sponsors: Genfleet Therapeutics (Shanghai) Inc.

Not yet recruiting Conditions: CRC
Interventions: Drug; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276; Drug: GFH276
Sponsors: Genfleet Therapeutics (Shanghai) Inc.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *